1. ALLA AKTIER
  2. NYHETER
  3. SANIONA

Saniona

Nyheter Saniona Nyheter alla bolag

Mexican Application for Tesofensine Not Yet Approved

MAR

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces that its partner, Productos Medix S.A de S.V (Medix), has not received approval from the Mexican regulatory agency (Cofepris) for tesofensine for the treatment of obesity. Instead, Medix is entering a dialogue with the agency regarding the path forward as it appears that the decision by Cofepris has not been based on the full data package as submitted by Medix.

The application is based on a Phase 3 program involving 372 patients conducted by Medix. The study confirmed compelling efficacy, with patients achieving an average weight loss of about ten percent in 24 weeks, and more than half of the patients experiencing a weight loss of more than ten percent. In general, tesofensine was very well tolerated, and a clinical safety database containing approximately 1600 patients provided a robust safety dataset.

For more information, please contact
Thomas Feldthus, CEO, +45 22109957; thomas.feldthus@saniona.com

About Saniona
Saniona (OMX: SANION) is a clinical-stage biopharmaceutical company leading the way in ion channel modulation for the treatment of epilepsy and other neurological disorders. Saniona’s epilepsy pipeline includes SAN711, a Phase 2-ready candidate for absence seizures; SAN2219, targeting acute repetitive seizures; and SAN2355, addressing refractory focal onset seizures. Beyond epilepsy, Saniona oversees four clinical programs poised for collaboration. Tesofensine for obesity is Saniona’s most advanced candidate and is out licensed to Medix in Mexico and Argentina. Tesomet™ is ready for Phase 2b, targeting rare eating disorders, while SAN903 is ready for Phase 1 for inflammatory bowel disease and SAN2465 is set for preclinical development for major depressive disorder. Saniona partners include Boehringer Ingelheim GmbH, Productos Medix S.A de S.V, AstronauTx Limited, and Cephagenix ApS. Saniona is based in Copenhagen and listed on Nasdaq Stockholm Main Market.
For more information, visit www.saniona.com.

This information is information that Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-06 08:00 CET.

Attachments
Mexican Application for Tesofensine Not Yet Approved

Datum 2024-11-06, kl 08:00
Källa MFN
Bifogade filer
Mexican Application for Tesofensine Not Yet Approved
Affiliate
200 kr till alla nya kunder! Just nu får alla nya kunder på Nordnet 200 kronor insatta i fonden Nordnet One Offensiv. Erbjudandet gäller mellan 1:e och 30:e september!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet